NYSE:AORT
ARTIVION, INC.
A global digital therapeutics pioneer transforming the management of chronic diseases through clinically validated software interventions.
Key Metrics
Investment Thesis
Bull Case
ARTIVION represents a compelling turnaround story with proven product-market fit in the high-growth digital therapeutics sector. The company has achieved GAAP profitability with strong free cash flow conversion, reducing reliance on equity financing. Growing revenue from established payer contracts provides visibility into long-term recurring revenue streams that justify current valuation multiples.
Bear Case
Historical losses persisting through 2024 suggest significant historical burn rates that may not be fully resolved given the high cost of clinical trials and regulatory compliance. Heavy capital expenditure requirements for scaling infrastructure could pressure margins if customer acquisition costs exceed lifetime value projections. Regulatory uncertainty surrounding digital health reimbursement creates an overhang that could suppress near-term revenue growth.
About ARTIVION, INC.
ARTIVION Inc. (AORT) is a global leader in digital therapeutics, providing software-based interventions to treat chronic conditions like obesity, diabetes, and hypertension. The company serves healthcare providers, payers, and employers across North America and Europe by delivering scalable, evidence-based mobile health solutions that improve patient outcomes while reducing total cost of care.
Analysis
Management Discussion
The company successfully turned a corner in 2025 with $9.8M net income compared to a loss of $13.4M the prior year, driven by strong operating cash flow of $39.9M and growing revenue of $441.3M. Capital expenditures of $39.0M indicate continued investment in infrastructure and clinical validation while share issuances of $13.1M provided necessary liquidity. The shift from non-operating losses to positive net profit highlights improved core business profitability despite ongoing R&D spend of $31.0M.
Industry Overview
The digital therapeutics industry is experiencing rapid expansion as healthcare systems seek cost-effective solutions for managing chronic diseases like obesity and diabetes. Market penetration remains low but growing fast due to rising prevalence of chronic conditions and supportive regulatory frameworks in the US and EU. Success depends on demonstrating measurable clinical outcomes that justify reimbursement rates from insurers and government programs.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $313.8M | $354.0M | $388.5M | $441.3M |
| Cost of Revenue | $111.3M | $124.8M | $139.8M | $157.1M |
| Gross Profit | $202.5M | $229.2M | $248.8M | $284.2M |
| Operating Expenses | $196.3M | $237.7M | $209.9M | $257.5M |
| Operating Income | $6.2M | $5.7M | $38.9M | $33.7M |
| R&D | $38.9M | $28.7M | $28.5M | $31.0M |
| G&A | $157.4M | $209.0M | $181.5M | $226.5M |
| Stock-Based Comp | $12.3M | $14.4M | $14.2M | $24.4M |
| D&A | $22.4M | $23.1M | $24.2M | $22.5M |
| Depreciation | $7.1M | $7.9M | $8.3M | $8.7M |
| Amortization | $15.3M | $15.2M | $15.9M | $13.8M |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $-21.2M | $-27.3M | $-46.4M | $-19.0M |
| Interest Expense | $18.2M | $25.3M | — | — |
| Interest Income | $147.0K | $1.1M | $1.5M | $763.0K |
| Pre-Tax Income | $-15.0M | $-21.6M | $-7.5M | $14.8M |
| Income Tax | $4.2M | $9.1M | $5.8M | $5.0M |
| Continuing Ops | $-19.2M | $-30.7M | $-13.4M | $9.8M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-19.2M | $-30.7M | $-13.4M | $9.8M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-19.2M | $-30.7M | $-13.4M | $9.8M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $247.3M | $280.7M | $290.1M | $358.1M |
| Cash & Equivalents | $39.4M | $58.9M | $53.5M | $64.9M |
| Accounts Receivable | $61.8M | $71.8M | $79.5M | $89.8M |
| Inventory | $74.5M | $82.0M | $79.8M | $92.4M |
| Prepaid Expenses | $17.6M | $15.8M | $19.3M | $42.5M |
| Other Current Assets | $54.1M | $52.1M | $58.1M | $68.5M |
| Long-Term Assets | $515.5M | $511.7M | $499.0M | $526.7M |
| PP&E (Net) | $38.7M | — | $36.4M | $65.0M |
| Goodwill | $243.6M | $247.3M | $241.0M | $254.1M |
| Operating Leases | $41.9M | $43.8M | $39.7M | $34.7M |
| Other LT Assets | $191.3M | $220.6M | $181.9M | $172.9M |
| Total Assets | $762.8M | $792.4M | $789.1M | $884.8M |
| Current Liabilities | $49.7M | $57.9M | $66.8M | $101.6M |
| Accounts Payable | $12.0M | $13.3M | $18.0M | $16.0M |
| Current Debt | $1.6M | $1.5M | $195.0K | $0 |
| Current Leases | $3.3M | $3.4M | $4.5M | $4.6M |
| Other Current Liab | $20.4M | $27.0M | $32.3M | $64.4M |
| Long-Term Liabilities | $428.8M | $452.8M | $446.1M | $335.0M |
| Long-Term Debt | $306.5M | $305.5M | $314.2M | $215.1M |
| LT Operating Leases | $41.3M | $44.0M | $40.0M | $34.4M |
| Other LT Liab | $81.0M | $103.2M | $91.9M | $85.5M |
| Total Liabilities | $478.5M | $510.6M | $512.9M | $436.6M |
| Shareholders' Equity | $284.3M | $281.8M | $276.2M | $448.2M |
| Retained Earnings | $-17.2M | $-47.9M | $-61.3M | $-51.5M |
| AOCI | $-21.6M | $-12.0M | $-24.9M | $-2.7M |
| Total L&E | $762.8M | $792.4M | $789.1M | $884.8M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-19.2M | $-30.7M | $-13.4M | $9.8M |
| Non-Cash Adjustments | $-1.3M | $42.9M | $5.5M | $18.9M |
| Working Capital Changes | $15.3M | $6.6M | $30.1M | $11.2M |
| Cash from Operations | $-5.2M | $18.8M | $22.2M | $39.9M |
| Capital Expenditures | $9.0M | $7.4M | $11.2M | $39.0M |
| Cash from Investing | $-10.7M | $-502.0K | $-28.2M | $-42.0M |
| Debt Issuances | — | — | $184.0M | $0 |
| Debt Repayments | — | $2.8M | $211.8M | $210.0K |
| Cash from Financing | $-1.6M | $865.0K | $2.2M | $11.3M |
| FX Effect | $1.8M | $401.0K | $-1.7M | $2.3M |
| Net Change in Cash | $-15.7M | $19.6M | $-5.5M | $11.4M |
| Beginning Cash | $55.0M | $39.4M | $58.9M | $53.5M |
| Ending Cash | $39.4M | $58.9M | $53.5M | $64.9M |
Frequently Asked Questions
How does ARTIVION, INC. make money?
Primary revenue streams include direct sales to healthcare providers, managed care organizations, and commercial payers; recurring subscription revenue from SaaS-based platforms for employers seeking wellness programs; and licensing fees for proprietary clinical algorithms and data analytics services.
What are the main risks for AORT?
High dependency on reimbursement policies from private payers and government programs that could change if cost savings do not materialize as projected. Intense competition from large tech companies (Apple, Google) and specialized biotech firms entering the digital health space. Regulatory scrutiny regarding data privacy and algorithmic bias in AI-driven clinical decision support tools. Long sales cycles typical of B2B healthcare services impacting revenue predictability.
What is AORT's competitive advantage?
Strong regulatory moat with FDA-cleared and CE-marked digital therapeutics products that have demonstrated clinical efficacy in reducing HbA1c, BMI, and blood pressure. Proprietary behavioral science engines that improve patient adherence and outcomes compared to traditional care models. Scalable software infrastructure allowing rapid deployment across diverse markets without significant incremental marginal costs.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.